195 related articles for article (PubMed ID: 6988911)
1. Therapeutic effect of tamoxifen related to estrogen receptor level.
Rose C; Thorpe SM; Løber J; Daenfeldt JL; Palshof T; Mouridsen HT
Recent Results Cancer Res; 1980; 71():134-41. PubMed ID: 6988911
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effect of tamoxifen alone versus tamoxifen in combination wtih gestagen and oestrogen in advanced breast cancer.
Mouridsen HT; Palshof T; Rose C
Recent Results Cancer Res; 1980; 71():169-77. PubMed ID: 6988913
[TBL] [Abstract][Full Text] [Related]
3. Principles and indications of endocrine treatment of advanced breast cancer.
Mouridsen HT; Palshof T
Recent Results Cancer Res; 1980; 71():112-7. PubMed ID: 7367722
[TBL] [Abstract][Full Text] [Related]
4. Influence of tamoxifen-medroxyprogesterone sequential therapy on estrogen and progesterone receptor contents of breast cancer.
Noguchi S; Yamamoto H; Inaji H; Imaoka S; Koyama H
Jpn J Cancer Res; 1989 Mar; 80(3):244-8. PubMed ID: 2524460
[TBL] [Abstract][Full Text] [Related]
5. Results with tamoxifen in advanced mammary carcinoma.
Kolb R; Jakesz R; Reiner H
Recent Results Cancer Res; 1980; 71():146-8. PubMed ID: 7367726
[TBL] [Abstract][Full Text] [Related]
6. Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer.
van Veelen H; Willemse PH; Tjabbes T; Schweitzer MJ; Sleijfer DT
Cancer; 1986 Jul; 58(1):7-13. PubMed ID: 2939943
[TBL] [Abstract][Full Text] [Related]
7. Alternating sequential endocrine therapy: tamoxifen and medroxyprogesterone acetate versus tamoxifen in postmenopausal advanced breast cancer patients.
Beltrán M; Alonso MC; Ojeda MB; Izquierdo A; Ferrer J; Picó C; Anglada L; Catalán G; Batiste-Alentorn E; Tusquets I
Ann Oncol; 1991 Jul; 2(7):495-9. PubMed ID: 1832944
[TBL] [Abstract][Full Text] [Related]
8. Treatment of breast cancer with medroxyprogesterone acetate.
Muggia FM; Cassieth PA; Ochoa M; Flatow FA; Gellhorn A; Hyman GA
Ann Intern Med; 1968 Feb; 68(2):328-37. PubMed ID: 4306126
[TBL] [Abstract][Full Text] [Related]
9. High progesterone receptor concentration in a variant of the ZR-75-1 human breast cancer cell line adapted to growth in oestrogen free conditions.
van den Berg HW; Martin J; Lynch M
Br J Cancer; 1990 Apr; 61(4):504-7. PubMed ID: 2139575
[TBL] [Abstract][Full Text] [Related]
10. Endocrine therapy testing of human breast cancers in the soft agar clonogenic assay.
Osborne CK; Von Hoff DD; Mullins K
Breast Cancer Res Treat; 1985; 6(3):229-35. PubMed ID: 2936413
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women.
Mouridsen HT; Ellemann K; Mattsson W; Palshof T; Daehnfeldt JL; Rose C
Cancer Treat Rep; 1979 Feb; 63(2):171-5. PubMed ID: 376131
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant endocrine therapy of breast cancer--a controlled clinical trial of oestrogen and anti-oestrogen: preliminary results of the Copenhagen breast cancer trials.
Palshof T; Mouridsen HT; Daehnfeldt JL
Recent Results Cancer Res; 1980; 71():185-9. PubMed ID: 6988914
[TBL] [Abstract][Full Text] [Related]
13. Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer.
Gundersen S; Kvinnsland S; Lundgren S; Klepp O; Lund E; Børmer O; Høst H
Breast Cancer Res Treat; 1990 Nov; 17(1):45-50. PubMed ID: 2151369
[TBL] [Abstract][Full Text] [Related]
14. [Effects of estrogen and endocrine therapeutic agents on the estrogen receptor, progesterone receptor and DNA synthesis in MCF-7 human breast cancer cells using the whole cell uptake method].
Kurebayashi J; Horiuchi R; Nakamura T; Iino Y; Ishida T; Takigawa H; Izuo M
Nihon Naibunpi Gakkai Zasshi; 1987 Nov; 63(11):1351-63. PubMed ID: 2965035
[TBL] [Abstract][Full Text] [Related]
15. [Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors].
Nomura Y; Tashiro H; Hisamatsu K; Toi M
Gan To Kagaku Ryoho; 1988 Mar; 15(3):513-8. PubMed ID: 2964811
[TBL] [Abstract][Full Text] [Related]
16. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis.
Ingle JN; Twito DI; Schaid DJ; Cullinan SA; Krook JE; Mailliard JA; Tschetter LK; Long HJ; Gerstner JG; Windschitl HE
Cancer; 1991 Feb; 67(4):886-91. PubMed ID: 1991261
[TBL] [Abstract][Full Text] [Related]
17. High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation.
Cuna GR; Calciati A; Strada MR; Bumma C; Campio L
Tumori; 1978 Apr; 64(2):143-9. PubMed ID: 354147
[TBL] [Abstract][Full Text] [Related]
18. High-dose medroxyprogesterone acetate (MPA) treatment in advanced breast cancer. A review.
Ganzina F
Tumori; 1979 Oct; 65(5):563-85. PubMed ID: 390798
[TBL] [Abstract][Full Text] [Related]
19. High dose medroxyprogesterone-acetate treatment in advanced mammary carcinoma. A phase II investigation.
Mattsson W
Acta Radiol Oncol Radiat Phys Biol; 1978; 17(5):387-400. PubMed ID: 162770
[TBL] [Abstract][Full Text] [Related]
20. The correlation of estrogen and progesterone receptor levels with response to chemotherapy for advanced carcinoma of the breast.
Paone JF; Abeloff MD; Ettinger DS; Arnold EA; Baker RR
Surg Gynecol Obstet; 1981 Jan; 152(1):70-4. PubMed ID: 7455895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]